Radionuclide imaging of myocardial metabolism

Circulation: Cardiovascular Imaging

Volumn 3, Issue 2, 2010, Pages 211-222

  Peterson, Linda R ^a   Gropler, Robert J ^b  

^a Department of Medicine   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart; Metabolism; PET; Radioisotopes

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; 15 (4 IODOPHENYL)PENTADECANOIC ACID; ACETIC ACID; CARBON 11; DEOXYGLUCOSE; FATTY ACID; FLUORINE 18; FLUORO 3,4 METHYLENEHEPTADECANOIC ACID F 18; FLUORO 4 THIAPALMITIC ACID F 18; FLUORO 6 THIAHEPTADECANOIC ACID F 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; IODINE 123; LACTIC ACID; OXYGEN 15; PALMITIC ACID; RADIOISOTOPE; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT;

AGING; CONGESTIVE CARDIOMYOPATHY; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AGE; ANIMAL; CARBOHYDRATE METABOLISM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIABETES MELLITUS; HEART DISEASE; HEART MUSCLE; METABOLISM; OXYGEN CONSUMPTION; SCINTISCANNING;

AGE FACTORS; ANIMALS; CARBOHYDRATE METABOLISM; DIABETES MELLITUS; FATTY ACIDS; GLUCOSE; HEART DISEASES; HUMANS; INSULIN RESISTANCE; MYOCARDIUM; OBESITY; OXYGEN CONSUMPTION; RADIOPHARMACEUTICALS; SEX FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77951930465     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.109.860593     Document Type: Review

References (100)

1. He ZX, Shi RF, Wu YJ, Tian YQ, Liu XJ, Wang SW, Shen R, Qin XW, Gao RL, Narula J, Jain D. Direct imaging of exercise-induced myocardial ischemia with fluorine-18-labeled deoxyglucose and Tc-99msestamibi in coronary artery disease. Circulation. 2003; 108: 1208-1213.
2. DeGrado TR, Holden JE, Ng CK, Raffel DM, Gatley SJ. Quantitative analysis of myocardial kinetics of 15-p-[iodine-125] iodophenylpentadecanoic acid. J Nucl Med. 1989; 30: 1211-1218.
3. Dormehl IC, Hugo N, Rossouw D, White A, Feinendegen LE. Planar myocardial imaging in the baboon model with iodine-123-15-(iodophenyl) pentadecanoic acid (IPPA) and iodine-123-15-(P-iodophenyl) - 3-R, S-methylpentadecanoic acid (BMIPP), using time-activity curves for evaluation of metabolism. Nucl Med Biol. 1995; 22: 837-847.
4. Eckelman WC, Babich JW. Synthesis and validation of fatty acid analogs radiolabeled by nonisotopic substitution. J Nucl Cardiol. 2007; 14: S100-S109.
5. Iida H, Rhodes CG, Araujo LI, Yamamoto Y, de Silva R, Maseri A, Jones T. Noninvasive quantification of regional myocardial metabolic rate for oxygen by use of 15O2 inhalation and positron emission tomography: theory, error analysis, and application in humans. Circulation. 1996; 94: 792-807.
6. Laine H, Katoh C, Luotolahti M, Yki-Jarvinen H, Kantola I, Jula A, Takala TO, Ruotsalainen U, Iida H, Haaparanta M, Nuutila P, Knuuti J. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy. Circulation. 1999; 100: 2425-2430.
7. Brown M, Marshall DR, Sobel BE, Bergmann SR. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation. 1987; 76: 687-696.
8. Brown MA, Myears DW, Bergmann SR. Noninvasive assessment of canine myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography. J Am Coll Cardiol. 1988; 12: 1054-1063.
9. Buck A, Wolpers HG, Hutchins GD, Savas V, Mangner TJ, Nguyen N, Schwaiger M. Effect of carbon-11-acetate recirculation on estimates of myocardial oxygen consumption by PET. J Nucl Med. 1991; 32: 1950-1957.
10. Sun KT, Yeatman LA, Buxton DB, Chen K, Johnson JA, Huang SC, Kofoed KF, Weismueller S, Czernin J, Phelps ME, Schelbert HR. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. J Nucl Med. 1998; 39: 272-280.
11. Gambhir SS, Schwaiger M, Huang SC, Krivokapich J, Schelbert HR, Nienaber CA, Phelps ME. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med. 1989; 30: 359-366.
12. Krivokapich J, Huang SC, Selin CE, Phelps ME. Fluorodeoxyglucose rate constants, lumped constant, and glucose metabolic rate in rabbit heart. Am J Physiol. 1987; 252: H777-H787.
13. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977; 28: 897-916.
14. Botker HE, Bottcher M, Schmitz O, Gee A, Hansen SB, Cold GE, Nielsen TT, Gjedde A. Glucose uptake and lumped constant variability in normal human hearts determined with [18F]fluorodeoxyglucose. J Nucl Cardiol. 1997; 4: 125-132.
15. Hariharan R, Bray M, Ganim R, Doenst T, Goodwin GW, Taegtmeyer H. Fundamental limitations of [18F]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake. Circulation. 1995; 91: 2435-2444.
16. Herrero P, Sharp TL, Dence C, Haraden BM, Gropler RJ. Comparison of 1-(11) C-glucose and (18) F-FDG for quantifying myocardial glucose use with PET. J Nucl Med. 2002; 43: 1530-1541.
17. Herrero P, Weinheimer CJ, Dence C, Oellerich WF, Gropler RJ. Quantification of myocardial glucose utilization by PET and 1-carbon-11-glucose. J Nucl Cardiol. 2002; 9: 5-14.
18. 11C-glucose and kinetic modeling. J Nucl Med. 2007; 48: 955-964.
19. 11C-lactate as a PET tracer of myocardial lactate metabolism: a feasibility study. J Nucl Med. 2007; 48: 2046-2055.
20. Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med. 1996; 37: 1723-1730.
21. Kisrieva-Ware Z, Coggan AR, Sharp TL, Dence CS, Gropler RJ, Herrero P. Assessment of myocardial triglyceride oxidation with PET and 11C-palmitate. J Nucl Cardiol. 2009; 16: 411-421.
22. DeGrado TR. Synthesis of 14 (R, S)-[18F]fluoro-6-thia-heptadecanoic acid (FTHA). J Label Comp Radiopharm. 1991; 29: 989-995.
23. DeGrado TR, Coenen HH, Stocklin G. 14 (R, S)-[18F]fluoro-6- thiaheptadecanoic acid (FTHA) : evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids. J Nucl Med. 1991; 32: 1888-1896.
24. Schulz G, von Dahl J, Kaiser HJ, Koch KC, Sabri O, Banneitz L, Cremerius U, Buell U. Imaging of beta-oxidation by static PET with 14 (R, S)-[18F]-fluoro-6-thiaheptadecanoic acid (FTHA) in patients with advanced coronary heart disease: a comparison with 18FDG-PET and 99Tcm-MIBI SPET. Nucl Med Commun. 1996; 17: 1057-1064.
25. Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure. J Nucl Med. 2001; 42: 55-62.
26. DeGrado TR, Kitapci MT, Wang S, Ying J, Lopaschuk GD. Validation of 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: effects of hypoxia and composition of exogenous fatty acids. J Nucl Med. 2006; 47: 173-181.
27. Shoup TM, Elmaleh DR, Bonab AA, Fischman AJ. Evaluation of trans-9-18F-fluoro-3, 4-Methyleneheptadecanoic acid as a PET tracer for myocardial fatty acid imaging. J Nucl Med. 2005; 46: 297-304.
28. Bing RJ. The metabolism of the heart. Harvey Lect. 1955; 50: 27-70.
29. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A. 2003; 100: 1226-1231.
30. Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, Stepkowski S, Davies PJ, Taegtmeyer H. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med. 1998; 4: 1269-1275.
31. Abu-Erreish GM, Neely JR, Whitmer JT, Whitman V, Sanadi DR. Fatty acid oxidation by isolated perfused working hearts of aged rats. Am J Physiol. 1977; 232: E258-E262.
32. McMillin JB, Taffet GE, Taegtmeyer H, Hudson EK, Tate CA. Mitochondrial metabolism and substrate competition in the aging Fischer rat heart. Cardiovasc Res. 1993; 27: 2222-2228.
33. Iemitsu M, Miyauchi T, Maeda S, Tanabe T, Takanashi M, Irukayama-Tomobe Y, Sakai S, Ohmori H, Matsuda M, Yamaguchi I. Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol. 2002; 283: H1750-H1760.
34. Kates AM, Herrero P, Dence C, Soto P, Srinivasan M, Delano DG, Ehsani A, Gropler RJ. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol. 2003; 41: 293-299.
35. Soto PF, Herrero P, Kates AM, Dence CS, Ehsani AA, Davila-Roman VG, Schechtman KB, Gropler RJ. Impact of aging on myocardial metabolic response to dobutamine. Am J Physiol Heart Circ Physiol. 2003; 285: 2158-2164.
36. Soto PF, Herrero P, Schechtman KB, Waggoner AD, Baumstark JM, Ehsani AA, Gropler RJ. Exercise training impacts the myocardial metabolism of older individuals in a gender-specific manner. Am J Physiol Heart Circ Physiol. 2008; 295: H842-H850.
37. Desrois M, Sidell RJ, Gauguier D, Davey CL, Radda GK, Clarke K. Gender differences in hypertrophy, insulin resistance and ischemic injury in the aging type 2 diabetic rat heart. J Mol Cell Cardiol. 2004; 37: 547-555.
38. Peterson LR, Soto PF, Herrero P, Schechtman KB, Dence C, Gropler RJ. Sex differences in myocardial oxygen and glucose metabolism. J Nucl Cardiol. 2007; 14: 573-581.
39. Peterson LR, Soto PM, Herrero P, Mohammed S, Avidan MS, Schechtman KB, Dence C, Gropler RJ. Impact of gender on the myocardial metabolic response to Obesity. J Am Coll Cardiol Imaging. 2008; 1: 424-433.
40. Mittendorfer B. Sexual dimorphism in human lipid metabolism. J Nutr. 2005; 135: 681-686.
41. Kendrick ZV, Ellis GS. Effect of estradiol on tissue glycogen metabolism and lipid availability in exercised male rats. J Appl Physiol. 1991; 71: 1694-1699.
42. Herrero P, Soto PF, Dence CS, Kisrieva-Ware Z, Delano DA, Peterson LR, Gropler RJ. Impact of hormone replacement on myocardial fatty acid metabolism: potential role of estrogen. J Nucl Cardiol. 2005; 12: 574-581.
43. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the Am Heart Association. Circulation. 1999; 100: 1134-1146.
44. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Cardiovasc Drugs Ther. 1994; 8: 65-73.
45. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res. 2006; 98: 596-605.
46. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 1997; 34: 25-33.
47. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007; 115: 3213-3223.
48. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes, II: potential mechanisms. Circulation. 2002; 105: 1861-1870.
49. Unger RH. Lipotoxic diseases. Annu Rev Med. 2002; 53: 319-336.
50. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109: 121-130.
51. Shoghi KI, Gropler RJ, Sharp T, Herrero P, Fettig N, Su Y, Mitra MS, Kovacs A, Finck BN, Welch MJ. Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation. J Nucl Med. 2008; 49: 1320-1327.
52. Welch MJ, Lewis JS, Kim J, Sharp TL, Dence CS, Gropler RJ, Herrero P. Assessment of myocardial metabolism in diabetic rats using smallanimal PET: a feasibility study. J Nucl Med. 2006; 47: 689-697.
53. Monti LD, Landoni C, Setola E, Galluccio E, Lucotti P, Sandoli EP, Origgi A, Lucignani G, Piatti P, Fazio F. Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in type 2 diabetic patients. Am J Physiol Heart Circ Physiol. 2004; 287: H1225-H1231.
54. Monti LD, Lucignani G, Landoni C, Moresco RM, Piatti P, Stefani I, Pozza G, Fazio F. Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients: role of free fatty acid and insulin levels. Diabetes. 1995; 44: 537-542.
55. vom Dahl J, Herman WH, Hicks RJ, Ortiz-Alonso FJ, Lee KS, Allman KC, Wolfe ER Jr, Kalff V, Schwaiger M. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic positron emission tomography. Circulation. 1993; 88: 395-404.
56. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, Gropler RJ. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol. 2006; 47: 598-604.
57. Herrero P, McGill JB, Lesniak D, Matthew S, Dence C, Scott S, Kisrieve-Ware Z, Gropler RJ. Pet detection of the impact of dobutamine on myocardial glucose metabolism in women with type 1 diabetes mellitus. J Nucl Cardiol. 2008; 15: 791-799.
58. Peterson LR, Herrero P, McGill J, Schechtman KB, Kisrieva-Ware Z, Lesniak D, Gropler RJ. Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes. Diabetes. 2008; 57: 32-40.
59. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000; 97: 1784-1789.
60. Hallsten K, Virtanen KA, Lonnqvist F, Janatuinen T, Turiceanu M, Ronnemaa T, Viikari J, Lehtimaki T, Knuuti J, Nuutila P. Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone. Diabet Med. 2004; 21: 1280-1287.
61. Commerford SR, Pagliassotti MJ, Melby CL, Wei Y, Gayles EC, Hill JO. Fat oxidation, lipolysis, and free fatty acid cycling in obesity-prone and obesity-resistant rats. Am J Physiol Endocrinol Metab. 2000; 279: E875-E885.
62. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004; 109: 2191-2196.
63. Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J. 2000; 139: S115-S119.
64. McNulty PH, Jagasia D, Cline GW, Ng CK, Whiting JM, Garg P, Shulman GI, Soufer R. Persistent changes in myocardial glucose metabolism in vivo during reperfusion of a limited-duration coronary occlusion. Circulation. 2000; 101: 917-922.
65. Abbott BG, Liu YH, Arrighi JA. [18F]Fluorodeoxyglucose as a memory marker of transient myocardial ischaemia. Nucl Med Commun. 2007; 28: 89-94.
66. Kawai Y, Tsukamoto E, Nozaki Y, Morita K, Sakurai M, Tamaki N. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol. 2001; 38: 1888-1894.
67. Tamaki N. Role of BMIPP imaging for risk stratification in patients with coronary artery disease. J Nucl Cardiol. 2005; 12: 148-150.
68. Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol. 2008; 51: 139-145.
69. Dilsizian V, Bateman TM, Bergmann SR, Des Prez R, Magram MY, Goodbody AE, Babich JW, Udelson JE. Metabolic imaging with betamethyl-p-[(123) I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation. 2005; 112: 2169-2174.
70. Abramson BL, Ruddy TD, deKemp RA, Laramee LA, Marquis JF, Beanlands RSB. Stress perfusion/metabolism imaging: a pilot study for a potential new approach to the diagnosis of coronary disease in women. J Nucl Cardiol. 2000; 7: 205-212.
71. 18F-FDG Uptake after exercise-induced myocardial ischemia in patients with coronary artery disease. J Nucl Med. 2008; 49: 1986-1991.
72. Barger PM, Kelly DP. Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci. 1999; 318: 36-42.
73. Rupp H, Jacob R. Metabolically-modulated growth and phenotype of the rat heart. Eur Heart J. 1992; 13: D56-D61.
74. Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I, Watkins H. Mutations in the gamma (2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet. 2001; 10: 1215-1220.
75. Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP, Staels B, World MJ, Doering A, Erdmann J, Hengstenberg C, Humphries SE, Schunkert H, Flavell DM. Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 2002; 105: 950-955.
76. Handa N, Magata Y, Mukai T, Nishina T, Konishi J, Komeda M. Quantitative FDG-uptake by positron emission tomography in progressive hypertrophy of rat hearts in vivo. Ann Nucl Med. 2007; 21: 569-576.
77. de las Fuentes L, Herrero P, Peterson LR, Kelly DP, Gropler RJ, Davila-Roman VG. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension. 2003; 41: 83-87.
78. de las Fuentes L, Soto PF, Cupps BP, Pasque MK, Herrero P, Gropler RJ, Waggoner AD, Davila-Roman VG. Hypertensive left ventricular hypertrophy is associated with abnormal myocardial fatty acid metabolism and myocardial efficiency. J Nucl Cardiol. 2006; 13: 369-377.
79. Tuunanen H, Kuusisto J, Toikka J, Jaaskelainen P, Marjamaki P, Peuhkurinen K, Viljanen T, Sipola P, Stolen KQ, Hannukainen J, Nuutila P, Laakso M, Knuuti J. Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study. J Nucl Cardiol. 2007; 14: 354-365.
80. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001; 104: 2923-2931.
81. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation. 2004; 110: 894-896.
82. Nakae I, Mitsunami K, Omura T, Yabe T, Tsutamoto T, Matsuo S, Takahashi M, Morikawa S, Inubushi T, Nakamura Y, Kinoshita M, Horie M. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol. 2003; 42: 1587-1593.
83. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002; 40: 271-277.
84. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation. 2006; 114: 2130-2137.
85. Beanlands RS, Nahmias C, Gordon E, Coates G, deKemp R, Firnau G, Fallen E. The effects of beta (1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study. Circulation. 2000; 102: 2070-2075.
86. Stolen KQ, Kemppainen J, Ukkonen H, Kalliokoski KK, Luotolahti M, Lehikoinen P, Hamalainen H, Salo T, Airaksinen KE, Nuutila P, Knuuti J. Exercise training improves biventricular oxidative metabolism and left ventricular efficiency in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2003; 41: 460-467.
87. Sundell J, Engblom E, Koistinen J, Ylitalo A, Naum A, Stolen KQ, Kalliokoski R, Nekolla SG, Airaksinen KE, Bax JJ, Knuuti J. The effects of cardiac resynchronization therapy on left ventricular function, myocardial energetics, and metabolic reserve in patients with dilated cardiomyopathy and heart failure. J Am Coll Cardiol. 2004; 43: 1027-1033.
88. Tuunanen H, Engblom E, Naum A, Nagren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008; 118: 1250-1258.
89. Hasegawa S, Kusuoka H, Maruyama K, Nishimura T, Hori M, Hatazawa J. Myocardial positron emission computed tomographic images obtained with fluorine-18 fluoro-2-deoxyglucose predict the response of idiopathic dilated cardiomyopathy patients to beta-blockers. J Am Coll Cardiol. 2004; 43: 224-233.
90. van Campen CM, Visser FC, van der Weerdt AP, Knaapen P, Comans EF, Lammertsma AA, de Cock CC, Visser CA. FDG PET as a predictor of response to resynchronisation therapy in patients with ischaemic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2007; 34: 309-315.
91. Oikawa M, Kagaya Y, Otani H, Sakuma M, Demachi J, Suzuki J, Takahashi T, Nawata J, Ido T, Watanabe J, Shirato K. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol. 2005; 45: 1849-1855.
92. Hicks RJ, Kalff V, Savas V, Starling MR, Schwaiger M. Assessment of right ventricular oxidative metabolism by positron emission tomography with C-11 acetate in aortic valve disease. Am J Cardiol. 1991; 67: 753-757.
93. Kim Y, Goto H, Kobayashi K, Sawada Y, Miyake Y, Fujiwara G, Chiba H, Okada T, Nishimura T. Detection of impaired fatty acid metabolism in right ventricular hypertrophy: assessment by I-123 beta-methyl iodophenyl pentadecanoic acid (BMIPP) myocardial single-photon emission computed tomography. Ann Nucl Med. 1997; 11: 207-212.
94. Magata Y, Kawaguchi T, Ukon M, Yamamura N, Uehara T, Ogawa K, Arano Y, Temma T, Mukai T, Tadamura E, Saji H. A Tc-99m-labeled long chain fatty acid derivative for myocardial imaging. Bioconjug Chem. 2004; 15: 389-393.
95. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstrom P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105: 2708-2711.
96. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006; 48: 1825-1831.
97. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006; 48: 1818-1824.
98. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, Fuster V, Fayad ZA. (18) Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007; 50: 892-896.
99. 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med. 2008; 49: 1277-1282.
100. Herrero P, Gropler RJ. Imaging of myocardial metabolism. J Nucl Cardiol. 2005; 12: 345-358.